https://scholars.lib.ntu.edu.tw/handle/123456789/543548
標題: | Increase of the resistance of human cervical carcinoma cells to cisplatin by inhibition of the MEK to ERK signaling pathway partly via enhancement of anticancer drug-induced NFκB activation | 作者: | Yeh P.Y. Chuang S.-E. KUN-HUEI YEH Song Y.C. Ea C.-K. ANN-LII CHENG |
公開日期: | 2002 | 卷: | 63 | 期: | 8 | 起(迄)頁: | 1423-1430 | 來源出版物: | Biochemical Pharmacology | 摘要: | In this study, we showed that suppression of the MEK-ERK transduction pathway by a selective inhibitor, 2′-amino-3′-methoxyflavone (PD98059), increased drug resistance of SiHa cells to cisplatin, but not to another common anticancer drug, doxorubicin. The downstream mechanism of this discrepant cellular response was investigated. Both cisplatin and doxorubicin activated nuclear ERK2 and nuclear transcription factor κB (NFκB) of SiHa cells. However, suppression of the MEK-ERK2 pathway by PD98059 resulted in a further enhancement of cisplatin-induced NFκB activation, while no further regulation of NFκB was noted in doxorubicin-treated cells. The activation of NFκB by cisplatin or doxorubicin was not due to the degradation of cytoplasmic IκBα, as demonstrated by western blotting. Transfection of a dominant negative IκBα resulted in a markedly diminished PD98059-induced cisplatin resistance in SiHa cells. Our results suggest that the MEK-ERK signaling pathway plays a role in the chemosensitivity of SiHa cells, and suppression of this pathway increases cisplatin resistance partly via an increase of NFκB activation. The mechanism responsible for the discrepant effect of PD98059 on NFκB activation and hence the chemosensitivity of SiHa cells towards cisplatin and doxorubicin remains to be investigated. ? 2002 Elsevier Science Inc. All rights reserved. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-0037091048&doi=10.1016%2fS0006-2952%2802%2900908-5&partnerID=40&md5=540cff34193674c126ce991ff775fb29 https://scholars.lib.ntu.edu.tw/handle/123456789/543548 |
ISSN: | 0006-2952 | DOI: | 10.1016/S0006-2952(02)00908-5 | SDG/關鍵字: | 2 (2 amino 3 methoxyphenyl)chromone; cisplatin; immunoglobulin enhancer binding protein; mitogen activated protein kinase; mitogen activated protein kinase 1; transcription factor; article; cancer cell culture; carcinoma cell; cell line; chemosensitivity; controlled study; drug effect; drug inhibition; drug resistance; drug selectivity; enzyme activation; gene repression; genetic transduction; genetic transfection; human; human cell; priority journal; protein degradation; signal transduction; uterine cervix carcinoma; Antineoplastic Agents; Cisplatin; DNA-Binding Proteins; Doxorubicin; Drug Interactions; Female; Flavonoids; Humans; I-kappa B Proteins; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinases; NF-kappa B; p38 Mitogen-Activated Protein Kinases; Signal Transduction; Transfection; Tumor Cells, Cultured; Uterine Cervical Neoplasms |
顯示於: | 腫瘤醫學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。